{"title": "Find a Doctor", "author": null, "url": "https://www.dana-farber.org/find-a-doctor/paul-g-richardson/", "hostname": "dana-farber.org", "description": "Paul G. Richardson, MD - Medical Oncology. After comprehensive training and certification in Internal Medicine, Hematology and Medical Oncology, as well as then acquiring additional expertise in Cancer Pharmacology and Transplant at Dana Farber Cancer Institute, I joined the Division of Hematologic Oncology and the Jerome Lipper Multiple Myeloma Cente...", "sitename": "Paul G. Richardson, MD - Dana-Farber Cancer Institute", "date": "2019-05-16", "cleaned_text": "Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol. 2023 Jul; 24(7):e293-e311. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37414019) Assessing the Ability of Long Noncoding RNA Expression to Predict Patient Outcomes in Pediatric AML. J Clin Oncol. 2023 Jun 30; JCO2300465. View Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN HORIZON myeloma. Blood. 2023 04 06; 141(14):1724-1736. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36603186) A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study. Future Oncol. 2022 in: patients with and active myeloma. JCI 02 08; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36752202) Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36209764) for isatuximab-treated patients with relapsed/refractory multiple myeloma: multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN J Haematol. 2022 11; 199(3):355-365. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36111391) Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J 41(3):568-578. therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes. Hematol. for the treatment of newly diagnosed multiple myeloma: a practical review. Br J Haematol. 2022 10; 199(2):190-204. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35796524) Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J. 2022 06 29; 12(6):98. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35768410) development of orthostatic hypotension during autologous stem cell transplant until Progression in Myeloma. N Engl J Med. plus Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer J. 2022 04 13; 12(4):63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35418120) An overview of treatment options for patients with relapsed/refractory multiple myeloma and bortezomib, and dexamethasone as induction therapy in patients diagnosed multiple Am J Hematol. 2022 05; 97(5):562-573. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35132679) Quality of life, psychological distress, and prognostic perceptions in patients with multiple refractory multiple myeloma (ICARIA-MM): follow-up analysis of 2022 03; 23(3):416-427. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35151415) of Selinexor in Multiple Myeloma in 2021: of emerging treatment in relapsed/ refractory [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35032434) Distinctive COVID-19 Syndromes. Shock. 2022 01 comparison with twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. Br J 2022 02; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34675390) to G. R. Mohyuddin et al and A. Garfall et al. protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. patients multiple myeloma: subgroup myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. Future Oncol. Multiple Res. 2021 12 01; 27(23):6432-6444. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34518309) Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory in Men and Women. N Engl J LAG3/GAL-3 to immunosuppression 01; 36(1):138-154. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34290359) Selinexor for the treatment of patients with previously treated multiple myeloma. Expert Rev Hematol. 2021 08; 14(8):697-706. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33985401) Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and previously treated multiple myeloma: Outcomes by cytogenetic risk. J 07 Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed Endothelium the Missing Link in the Pathophysiology and Treatment of Adv. 2021 06; 7(23). View in: 1b study of isatuximab short-duration fixed-volume infusion 35(12):3526-3533. in relapsed/refractory multiple with View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34036560) of efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone Discov. 2021 09; 2(5):468-483. selinexor, bortezomib, and in previously patients with relapsed/refractory multiple myeloma according to prior lines of treatment and status: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33839618) The initial management of multiple myeloma in the era of novel agents: 2021 and J Haematol. 2021 04; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33748954) Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation - a case series. Br J Haematol. 2021 05; 193(4):e36-e38. View plasmacytomas in multiple myeloma: definition, disease assessment and treatment Br J Haematol. 08; Treatment of refractory multiple myeloma: recommendations from the International Myeloma diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv. 2021 02 23; 5(4):1092-1096. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33606004) Molecular Haematol. 2021 05; 193(3):581-591. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33570193) Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. Blood Rev. 2021 09; 49:100808. View bortezomib?+?dexamethasone relapsed and in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33563894) COVID-19-induced endotheliitis: Haematol. 2021 04; 193(1):43-51. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33538335) A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J. 2021 02 04; 11(2):23. Injection: HIV Prevention Trials Network Study (HPTN 076). Hum long-term survival follow-up from the II 06; 193(6):1105-1109. View Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of with elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an plus newly myeloma. Blood. 2020 11 26; 136(22):2513-2523. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32735641) with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. 14; 396(10262):1563-1573. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33189178) Current antibody-based the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J. 2020 10 23; 10(10):106. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33097687) Overall survival of patients refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. 01; 96(1):E5-E8. Clin Med. 2020 Sep 27; 9(10). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32992506) Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Hematopoietic previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020 09 04; 10(9):91. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32887873) in in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, newly myeloma: the GRIFFIN trial. 2020 08 20; 136(8):936-945. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32325490) 2020 Oct; 29(10):1133-1141. Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Reveal a Outcome Group. J Clin 20; 38(27):3107-3118. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32687451) is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift? Br J 2020 12; 191(5):692-703. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32501533) Alcohol-related brain injury: unrecognized 2020 11; 88:49-53. View adults: a secondary analysis of the HPTN 077 trial. HIV. 2020 07; 7(7):e472-e481. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32497491) Daratumumab monotherapy pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 Jun; in myeloma patients with non-canonical NF-?B Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389. OPTIMISMM. Allogeneic 26(8):1414-1424. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32325171) c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma bortezomib. 076: A phase [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32280940) Defibrotide formulations contain (1?3)-\u00df-D-glucan that could influence clinical diagnostic testing. Bone Marrow Transplant. 2020 10; 55(10):2045-2046. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32231251) Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients. Biol Blood Marrow Transplant. 2020 07; 26(7):1342-1349. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32200121) Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. Br J Haematol. 2020 08; 190(4):583-587. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32157682) Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, Hematol. 2020 04; 13(4):421-433. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32148109) Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. Blood Cancer J. 2020 03 04; 10(3):29. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32132522) Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple Invest New Drugs. 2020 10; 38(5):1448-1453. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32125598) Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad? Cells. 2020 02 06; 9(2). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32041300) View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31859245) Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol. 2020 Jan; 7(1):e61-e72. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31818728) Publisher Correction: Systematic of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). Bone Marrow myeloma (ICARIA-MM): a randomised, multicentre, open-label, 07; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31735560) Incidence, Predictors, after Reduced-Intensity Allogeneic Hematopoietic Cell Marrow 26(3):529-539. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31678537) Phase Ib/II Trial Anti-CXCR4 Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. 26(2):344-353. View Clinical Trial Representativeness in Real-World Patients: Comparison of 6 Hallmark HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074. PLoS One. 2019; plerixafor combination with bortezomib as a chemosensitization relapsed/refractory multiple 94(11):1244-1253. preemptive, and treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant. 2020 03; 55(3):485-495. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31576023) Pomalidomide in lenalidomide-refractory 08 22; 381(8):727-738. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31433920) Use of Antiretroviral Drug Testing to Assess the Accuracy of Self-reported Data from HIV-Infected People Who Inject Drugs. AIDS Behav. 2019 Aug; 23(8):2101-2108. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30600453) Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. Aliment Pharmacol Ther. 2019 08; 50(4):442-453. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31313853) Towards a better understanding of monoclonal gammopathy of renal significance. Br J View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31134621) Validation of HIV-infected cohort identification using automated clinical data in the Department of Veterans Affairs. HIV Med. 2019 09; 20(8):567-570. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31131549) Pomalidomide, bortezomib, myeloma previously treated with lenalidomide (OPTIMISMM): a 20(6):781-794. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31097405) Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. Eur J Haematol. 2019 Jun; 102(6):494-503. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30943323) A Clinician's Perspective of Elotuzumab Antitumor Res. 2019 May 01; 25(9):2938. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31043386) Study protocol for a randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2019 Apr; 33(4):1058-1059. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30842604) Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. J Haematol. 2019 08; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30931524) copy myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019 03 20; 9(4):37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30894515) Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in 2019 09; 33(9):2208-2226. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30872779) 2019 07 11; 134(2):123-133. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30862646) The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. Addiction. 2019 06; 114(6):1113-1122. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30694582) Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. Am J Hematol. 2019 05; 94(5):E146-E149. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30773670) Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). Bone Marrow Ixazomib, and newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 2019 07; 33(7):1736-1746. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30696949) Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical JAMA Oncol. 2018 12 View the International Myeloma Working Group myeloma frailty score among patients 75 and J Geriatr Oncol. 2019 05; 10(3):486-489. View in: Dec; relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018 12; 19(12):1641-1653. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30442502) Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018 11 09; 8(11):109. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30413684) View A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2019 01 15; 25(2):478-486. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30279233) Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis. J Int AIDS Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis. Case Rep Hematol. 2018; 2018:3029650. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30345126) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. 12 06; 132(23):2456-2464. Transplantation Outcomes Germ-Cell the Modern Era. 4-year follow-up analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 10 15; 124(20):4032-4043. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30204239) A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. Lancet. 2018 09 01; 392(10149):747-759. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30191830) APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 2019 02; 33(2):426-438. Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Blood Marrow Transplant. 2019 01; 25(1):137-144. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30081073) The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30054438) Maintenance and continuous therapy Anticancer Ther. 2018 08; 18(8):751-764. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29932776) How I treat the young patient with multiple myeloma. Blood. 2018 09 13; 132(11):1114-1124. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29967130) Secondary plasma cell leukemia: a study patients. Leuk Lymphoma. 01; 60(1):118-123. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29965787) The use of defibrotide in and marrow lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. Br J Haematol. 2018 07; 182(2):231-244. disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program. Pediatr Blood Cancer. 2018 10; in patients with multiple myeloma: phase 2 study. Br J Haematol. 2018 08; 182(4):495-503. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29808907) Healthcare resource utilization ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study myeloma patients treated with panobinostat after =2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29774521) Final results study for patients with hepatic veno-occlusive disease/sinusoidal J Haematol. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29767845) Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. Br J Haematol. 2018 05; 181(4):433-446. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29748955) changes Haematologica. 2018 08; 103(8):1380-1389. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29748440) lenalidomide, bortezomib and dexamethasone in transplant-ineligible [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29740809) health-related quality life the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Am J Hematol. 2018 May 04. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29726031) Current use of monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2018 05; 181(4):447-459. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29696629) Letter to the Editor: Response to Costa et al. Eur Neuropsychopharmacol. 2018 05; 28(5):658. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29655506) Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Clin multiple myeloma: an overview and IMWG consensus. Ann Long intergenic non-coding RNAs have an independent impact on survival in myeloma. Leukemia. 2018 12; 32(12):2626-2635. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29749396) sequencing. Leukemia. 2018 08; 32(8):1838-1841. the Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Hum Retroviruses. 2018 05; 34(5):421-429. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29455571) Association between response and outcomes in relapsed/refractory multiple myeloma: analysis cytotoxic T lymphocytes against multiple myeloma and tumors. Leukemia. 2018 09; 32(9):1932-1947. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29487385) Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. Br J Haematol. 03; maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. Bone Marrow 2018 07; 53(7):942-945. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29426830) Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. sodium for the Oncol. May; combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018 02; 32(2):252-262. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29257139) CD38 antibodies in multiple myeloma: back to the future. Blood. 2018 01 04; 131(1):13-29. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29118010) A phase 1 clinical trial marizomib, pomalidomide low-dose dexamethasone in relapsed and refractory multiple final nanoparticles arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple Br J Haematol. 2018 01; 180(2):271-275. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29048105) and Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28803351) Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase protocols for alcohol use used in Eur Neuropsychopharmacol. 2017 11; 27(11):1077-1089. View with hepatic veno-occlusive cell in: Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Ann Intern Med. 2017 Sep 19; 167(6):384-393. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28828489) New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. J Blood Med. 2017; 8:107-121. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28860887) Updated analysis of CALGB (Alliance) assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a Nov; for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018 02; 53(2):138-145. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28759025) Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28742454) Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents, Part 1: Focus on Investigations, Prophylaxis, and Specific Treatment. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1817-1825. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28754544) Prospective Evaluation Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: 06; View and post-hoc analyses and Its Combination With ISS in an Independent Cohort of Patients With Multiple and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. Br J Haematol. 2017 10; 179(1):66-74. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28653400) Adverse event management patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose 2017 Jun 08. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28621266) Synthesis and preliminary PET imaging of 11C J Hematol. 2017 Aug; 92(8):746-751. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28383205) A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. Alcohol. 2017 2017 12; 31(12):2661-2669. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28487543) Management of adverse with ixazomib plus relapsed/refractory View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28479592) A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28379796) Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Oncol. 2017 Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Biol Blood Transplant. 2017 Jun; 2017 02 01; 28(2):228-245. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27864218) Phase of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305). J [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27811319) p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 03 Inhibitor, Combination with Bortezomib and Dexamethasone Relapsed or Multiple 07 With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. Gastroenterology. 2017 04; 152(5):1068-1077.e4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28043903) Trends in 2000-2014. Leukemia. 2017 09; 31(9):1915-1921. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28008176) A 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical 22; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27764795) Deacetylase inhibitors as a novel myeloma. Pharmacol Res. Acad A. 113(46):13162-13167. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27799547) Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult 2017 05; 31(5):1059-1068. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27795558) Overall of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, on elotuzumab, a novel anti-SLAMF7 monoclonal antibody the treatment Ther. 2016 daratumumab, lenalidomide, and dexamethasone for relapsed multiple 128(14):1821-1828. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27531679) Point/Counterpoint: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma. One Size does not fit all. Oncology (Williston Park). 2016 08; 30(8):747-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27528243) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 08; 17(8):e328-e346. Disease: Final Results From the International Compassionate-Use Program. Blood Marrow Transplant. 2016 10; 22(10):1874-1882. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27397724) Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clin relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leuk 12; 57(12):2833-2838. View investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin efficacy of monotherapy patients with heavily pretreated relapsed or refractory myeloma. Blood. 2016 07 07; 128(1):37-44. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27216216) Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016 Jul; 51(7):906-12. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27183098) Marizomib hyperactivation multiple myeloma and solid tumour patients. Br J 2016 Sep; 174(5):711-20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27161872) APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. apoptosis and overcomes drug resistance myeloma cells. Leukemia. 2016 11; 30(11):2187-2197. DNA and cytotoxicity Haematol. 2016 08; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27098276) Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2016 07; 22(7):1306-1312. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27108694) The Future of Myeloma Therapy: One Size Does Not Fit All. J Apr; 12(4):295-6. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27049458) Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27009059) Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clin Cancer Res. 2016 Aug 15; 22(16):4206-4214. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27006493) International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol. 2016 05 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26976420) Phase trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016 Mar 31; 127(13):1656-65. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26825712) Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. 2016 Apr; 173(1):82-8. View in: is randomised, phase 387(10027):1551-1560. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26778538) The KDM3A-KLF2-IRF4 axis Jan 7:10258. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26728187) Res. 169:169-194. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27696263) Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2016 05; 30(5):1005-17. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26710887) Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 Mar 03; 127(9):1138-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26675349) Multiple Myeloma in Pregnancy--A Review Literature Case dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016 Feb 11; 127(6):713-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26631116) Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016 Feb 11; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26631114) Combination of a Selective a Signaling Pathway Inhibitor in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26630652) The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2?\u00d7?2 factorial randomised [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26691209) Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical Dec; 171(5):798-812. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26456076) Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064. PLoS One. 2015; 10(10):e0140074. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26445283) American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2039-2051. View Panobinostat for the Treatment 2015 Nov 01; 21(21):4767-73. View in: SAR650984 directly death via lysosomal-associated and apoptotic pathways, which is further enhanced 24; 373(13):1207-19. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26308596) Hematopoietic Cell Medication-Related Osteonecrosis the Jaws. Biol Blood View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26303103) Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma. Leukemia. 2016 Feb; 30(2):379-89. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26293646) Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015 Aug 13; 126(7):921-2. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26272048) Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. profiling dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016 View in: in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26139427) Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Cancer Discov. 2015 novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Myeloma. J Med. 2015 Aug 13; 373(7):621-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26035255) Promising therapies in 126(3):300-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26031917) Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26032514) Lenalidomide Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18. View in: Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood J. 2015 May 15; 5:e312. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25978432) Prednisolone or pentoxifylline for Med. 2015 Apr 23; 372(17):1619-28. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25901427) Jul 01; 23(13):3408-13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25963824) Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? Res. 2015 Jun 15; 21(12):2660-2. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25878332) Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058. J Acquir na\u00efve patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015 Jun; 50(6):781-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25798682) Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015 Jun; 55(6 Pt 2):1545-54. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25764134) Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015 Apr; 90(4):314-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25557740) Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer. 2015 Sep; 23(9):2789-97. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25708126) Management of relapsed multiple myeloma after autologous stem cell transplant. Biol Blood Marrow Transplant. 2015 May; 21(5):793-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25652690) Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015 Jun; 29(6):1441-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25634684) predicts in elderly myeloma patients: an International Myeloma Working Blood. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25628469) The 2015; 11(8):1153-68. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25832873) The association between the ratio of monocytes: lymphocytes and risk of tuberculosis among HIV-infected postpartum Combo Ag/Ab enzyme immunoassay for diagnosis of HIV infection in Southern J Clin Virol. 2015 Jan; 62:75-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25542477) Current treatment relapsed multiple Rev Clin Oncol. 2015 Jan; 12(1):42-54. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25421279) Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology Am Soc Program. tolerability proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014 Dec; 15(13):1503-1512. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25456369) Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT). Value Health. 2014 Nov; 17(7):A617-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27202167) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov; 15(12):e538-48. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25439696) Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease. BMC Genomics. 2014 Oct 17; 29(2):510-4. 100(1):100-6. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25261096) Differential and limited expression of mutant alleles in multiple myeloma. Blood. 2014 Nov placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25242045) Anaemia in pregnancy associated One. 2014; 9(9):e106103. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25222119) Veterans population: development and validation of an algorithm for NAFLD using Ther. 2014 Oct; 40(8):949-54. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25155259) Novel the treatment of multiple myeloma. Hematol Oncol Clin North Am. The challenge of cross-trial 2014 Aug; 99(8):e145-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25082787) Biomarkers of bone in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24958808) Allogeneic transplantation in multiple myeloma: a potential renaissance in the era of novel therapies? Biol Blood Marrow Transplant. 2014 in a long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand. Drug Alcohol Depend. 2014 Sep 01; 142:139-45. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24999060) Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res. 2014 Aug 15; 74(16):4458-69. View in: 1 oral proteasome inhibitor, in relapsed/refractory 2014 Aug 14; 124(7):1038-46. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24920586) Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol. 2014 cytotoxic T lymphocytes in T cells of smoldering 2015 29(1):218-29. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24935722) Lenalidomide desensitization for delayed hypersensitivity in 5 with multiple myeloma. Br J Haematol. 2014 2014 Jun; 20(6):599-606. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24813251) Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24761838) and with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible 2014 combination lenalidomide dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J. 2014 Apr 11; 4:e202. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24727998) Prevalence and seroincidence of hepatitis B and hepatitis C infection in high risk people who inject drugs in china and Thailand. Hepat Res Treat. 2014; 2014:296958. View in: and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa. J Acquir Immune Defic Syndr. 2014 Mar (GSK2857916) selectively killing of May 15; 123(20):3128-38. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24569262) Vorinostat in combination with lenalidomide dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J. 2014 02 21; 4:e182. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24562384) Daratumumab granted 23(4):445-52. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24555809) with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014 Mar; 15(3):333-42. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24525202) The comprehensive clinical management of multiple myeloma and related-plasma cell disorders. Expert Rev Hematol. 2014 Aug; 28(8):1716-24. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24476765) Current strategies for treatment Rev Hematol. 2014 Feb; 7(1):97-111. phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and 2014 Mar 06; 123(10):1461-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24429336) International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. in dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 20; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24421329) Heterogeneity of of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014 Jan 01; significantly reduces myeloma sensitivity to single-agent therapy. Blood. 2014 Jan 30; 123(5):632-9. View UCHL5 induces apoptosis in resistance. Blood. 2014 Jan 30; 123(5):706-16. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24319254) New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014 Mar; 28(3):525-42. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24253022) HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial. J Acquir Immune anti-CS1 the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets. Semin Oncol. 2013 Oct; 40(5):537-48. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24135398) Evolving Semin Oncol. 2013 Oct; 40(5):592-601. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24135404) Semin Oncol. 2013 Oct; 40(5):549-53. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24135399) Phase transitions IgG Sep and dysphagia. Burns. 2014 May; 40(3):436-42. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24041514) Phase Ib study of panobinostat bortezomib in or relapsed and refractory multiple Oncol. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials. 2013 Aug 19; 14:262. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23958271) PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory 03; 122(14):2331-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23950178) Histone deacetylase 3 as a therapeutic target myeloma. Leukemia. 2014 Mar; 28(3):680-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23913134) IgD and 2013 Aug; 27(8):803-4, Nephrol. 2013 Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8. View training improves cutaneous of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. J Acquir Immune Defic impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014 Jan; 28(1):155-65. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23588715) The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol. 2013 of novel alkylating agent, melphalan-flufenamide, against myeloma cells. Jun 01; 19(11):3019-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23584492) Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013 Jul; 37(7):829-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23582718) Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants. Pediatr Infect Dis J. 2013 Apr; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23249916) Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration. Biol Blood Marrow Transplant. 2013 Jun; 19(6):858-9. View prevalence of eosinophilic oesophagitis: a prospective study in humans. Blood. 2013 Apr 11; 121(15):2975-87. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23321256) Results of a of the deacetylase inhibitor panobinostat 21; 121(8):1296-303. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23287861) New insights into the Dec 27; 4(12):402-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23355920) Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and Mar 121(11):1961-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23243282) Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23240658) Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. Clin Oncol. 2013 Feb 01; 31(4):448-55. Drug of 2013 Jan; Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr; 27(4):780-91. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23288300) Atypical presentation of miliary cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S88-90. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23089567) Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit. Aliment Pharmacol Ther. 2012 Dec; 36(11-12):1049-56. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23061548) Sequence analysis of \u00df-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. MLN9708/2238 08; 120(19):3958-67. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22983447) Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. Br J Haematol. 2012 Nov; 159(3):340-51. induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11; 22(3):345-58. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22975377) Targeting NAD+ salvage pathway for the treatment Cancer Manag Res. 2012; 4:253-68. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22956884) Safety and efficacy of defibrotide treatment hepatic 109(33):13359-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22847421) Acute variceal bleeding in Gut. 2013 May; 62(5):740, 759. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22842616) How I treat plasma leukemia. Blood. 2012 Sep 20; 120(12):2376-89. View antitumor tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012 Aug 30; 120(9):1877-87. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22689860) Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across with cyclophosphamide, treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Rev Hematol. 2012 in: and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol. 2012 Aug; 158(4):472-80. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22640031) Proteasome inhibitors in myeloma: later. Blood. 2012 Aug 02; 120(5):947-59. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22645181) Discovery of pyrroloaminopyrazoles as novel PAK inhibitors. J Med Chem. 2012 May 24; 55(10):4728-39. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22554206) Lenalidomide after stem-cell transplantation 2012 May 10; 366(19):1770-81. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22571201) Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur 2012 Jul; 89(1):16-27. View the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and activity. May; 8(5):623-33. View in: of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. 2012 May; 26(5):1153. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22569269) Blockade of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun 14; 119(24):5772-81. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22538852) Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br J Haematol. 2012 Jun; 157(6):718-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22533681) schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on 2012 Sep; 26(9):1185-93. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22526685) Randomized, combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated 2012 May 10; 119(19):4375-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22422823) The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22300348) Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012 Feb 21; 9(3):135-43. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22349016) A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012 Mar 22; 119(12):2764-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22323483) Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8. for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22289890) Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. IMWG consensus on maintenance therapy myeloma. Blood. 2012 Mar 29; 119(13):3003-15. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22271445) 2012 Apr; 26(4):595-608. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22193964) Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22196945) The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21991938) Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Science. 2011 Nov 25; 334(6059):1129-33. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22033517) Persistent abdominal with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. J Med Chem. 2011 Nov 10; 54(21):7693-704. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21936524) Management panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma 2011 Oct; novel modulator SRT1720 multiple myeloma View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21950728) BET bromodomain inhibition as a strategy to c-Myc. Cell. 2011 Sep 16; 146(6):904-17. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21889194) An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation. Immunotherapy. 2011 Sep; 3(9):1033-40. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21913826) A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058. Int J Drug Policy. 2012 Mar; 23(2):162-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21852093) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group 26(1):149-57. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21799510) Cancer and relapse myeloma: prognostic and potential 96(11):1662-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21791470) Monoclonal Haematol. 2011 Sep; 154(6):745-54. myeloma: 2011; 6(7):e20226. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21750699) Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62. and in vivo activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma 15; 17(16):5311-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21724551) Anti-tumor activity and phenethyl MGUS 2011 Jun; 25(7):594, 596. phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21630305) phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma. patients with relapsed multiple myeloma: A randomized phase II study. J Clin Oncol. 2011 May 20; 29(15_suppl):8014. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28023004) Phase study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. J double-blind, placebo phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood. 2011 Jul 21; 118(3):535-43. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21596852) Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol. 2011 Jun; 153(6):729-40. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21534941) Comfort care in burns: the Burn Modified Liverpool Care Pathway (BM-LCP). Burns. 2011 Sep; 37(6):981-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21493007) Multiple myeloma and amyloidosis: an evolving treatment paradigm toward the goal of tailored therapy. J Clin Oncol. 2011 May 10; 29(14):1801-2. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21483011) Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011 May and inhibits Blood. 2011 May 26; 117(21):5692-700. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21454451) Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol. 2011 May; 86(5):372-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21366694) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011 Jun 09; 117(23):6063-73. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21447828) Hematology: Setting the standard for multiple Rev Clin Oncol. 2011 May; 8(5):255-6. View relapsed and multiple myeloma. Cancer Res. 2011 Mar 15; Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. Br J Haematol. 2011 Apr; 153(2):212-21. View in: for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar; 11(3):254-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21247382) A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics. 2011 Apr; 11(8):1391-402. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21365752) Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011 Apr 28; 117(17):4409-19. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21321360) Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 05; 117(18):4691-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21292775) Thalidomide, lenalidomide and bortezomib in management of diagnosed multiple myeloma. Expert Rev Hematol. 2011 cyclin-dependent kinase inhibition in myeloma: biological and 2011 Feb; 152(4):420-32. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21223249) Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011 Feb; 8(1):8-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21179054) A new standard of care in newly diagnosed multiple myeloma. Lancet. 2010 Dec 18; 376(9758):2043-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21146204) Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with therapeutic index Blood. 2010 Dec 02; 116(23):4733-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21127178) Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011 Jan; 86(1):23-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20874823) Towards a better of neuropathy myeloma. Lancet [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21051016) Vaccination fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21030562) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010 Nov 20; 28(33):4976-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20956629) Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr\u00f6m Am J Hematol. 2010 Sep; novel orally active proteasome ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple Blood. 2010 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20805366) Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28; 116(17):3227-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20651070) Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J 2010 Aug; in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20694078) Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010 Jul; 24(7):1350-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20508619) PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010 Sep 02; 116(9):1460-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20505158) Kidney disease associated with plasma dyscrasias. Blood. 2010 Sep 02; 116(9):1397-404. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20462963) The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010 Jun; 24(6):1121-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20410922) Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20395418) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; discovered through systematic combination screening in B-cell malignancies. Blood. 2010 Jul prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010 May 01; 28(13):2259-66. platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20228816) A proto-oncogene BCL6 the bone marrow microenvironment in multiple myeloma cells. Blood. 2010 May 06; 115(18):3772-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20228272) Blockade of the MEK/ERK signalling AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and J Haematol. 2010 May; 149(4):537-49. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20331454) Tailoring treatment for myeloma patients with relapsed disease. endothelial Blood Marrow Transplant. 2010 Aug; 16(8):1180-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20184961) The evolution and impact of therapy in multiple myeloma. Med Oncol. 2010 Jun; 27 Suppl 1:S1-6. of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding Jul; 16(7):1005-17. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20167278) Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20142598) Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and Waldenstrom [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20142586) Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 201-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20118399) Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22; 29(16):2325-36. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20101221) Assembly of 500,000 inter-specific catfish expressed sequence tags and large scale gene-associated marker development for whole genome association studies. may enhance the antitumor activity of Res. 2009 Dec of novel proteasome vitro and in cytotoxicity in myeloma. Blood. 2010 Jan View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19965674) How I treat multiple myeloma in younger patients. Dec [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19861683) VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol. 2009 Dec 20; 27(36):6086-93. View in: plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 06; 16(4):309-23. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19800576) Novel therapies in relapsed and disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010 Feb; 16(2):157-68. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19766729) vitro anti-myeloma 2009 Dec; 147(5):672-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19751238) The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009 Dec; 23(12):2222-32. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19741729) Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Int J Res. 2009 Sep 08; 1:107-17. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21188129) Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple J Nov; 147(4):531-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19725827) Use of defibrotide in the treatment and prevention of veno-occlusive disease. Expert Rev Hematol. 2009 Aug; 2(4):365-76. View rapamycin Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19561323) International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009 Oct; 23(10):1904-12. Single-agent bortezomib in previously untreated myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. cytotoxicity myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15; 15(12):4028-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19509164) International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009 Oct; 23(10):1716-30. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19494840) Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009 Jul 23; 114(4):772-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19471019) Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study. Clin Oncol. 2009 May 20; 27(15_suppl):8503. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27960855) Phase II trial of combination bortezomib and in relapsed and/or Encouraging outcomes and tolerability in a phase II study. J Clin Oncol. 2009 May 20; 27(15_suppl):8536. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27960933) of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer. J Clin Oncol. multiple myeloma: Initial results of phase I/II MMRC trial. 2009 May 20; 27(15_suppl):8517. of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study. J Clin Oncol. 2009 May 20; 27(15_suppl):8586. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27962293) Effect of the specific P53 stabilizer CBS9106 on multiple myeloma (MM). J nuclear Blood. 2009 Jul 30; 114(5):1046-52. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19436050) Clinical challenges associated [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19452315) benefit of novel therapies in multiple myeloma. Oncology (Williston Park). 2009 Apr 30; 23(5):415-6, 419. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19476274) Emerging treatments Blood. 2009 May 21; 113(21):5228-36. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19270264) Emerging therapies Mar; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19231786) Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res. 2009 Feb 15; 15(4):1210-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19228727) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009 Mar; 144(6):895-903. View cyclin-dependent kinase inhibitor in the May; 23(5):961-70. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19151776) International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009 Feb; 23(2):215-24. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19020545) Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol. 143(4):511-9. View analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18783399) Sirolimus is veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008 Dec 01; 112(12):4425-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18776081) Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics. 2008 Sep; 2(3):419-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19707373) Identification infected administrative initial treatment of multiple myeloma. N Engl J Med. 2008 Aug 28; 359(9):906-17. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18753647) Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. J Haematol. Oct; 143(2):222-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18713253) Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood. 2008 Nov 15; 112(10):4343-52. View in diagnosis and treatment of colorectal cancer: determinants and association with cancer stage and survival. Pharmacol Ther. 2008 Nov 01; 28(9):1166-74. View in: in Feb; 23(2):422-3; author reply 423-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18685616) The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. 143(1):46-53. Leukemia. Oct; 22(10):1925-32. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18596740) Bortezomib organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008 Jul 01; 68(13):5216-25. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18593922) Lenalidomide plus dexamethasone is efficacious multiple evolving treatment paradigm of multiple myeloma: From past to present and future. Turk J Haematol. 2008 Jun 05; 25(2):60-70. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27264441) Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or May 26(15_suppl):19522. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27949394) Long-term responses observed with lenalidomide therapy for patients with relapsed or refractory multiple myeloma. Clin Oncol. on tumour adhesion and invasion in multiple myeloma, breast cancer and renal cell cancer. J Clin Oncol. 2008 May 20; MM-014: relapsed and Oncol. 2008 May of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM). J Clin Oncol. 2008 May of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study. pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. bisphosphonate-associated osteonecrosis of the jaws. Oral characterization multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. Apr 15; 14(8):2387-95. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18413829) Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br J Haematol. 2008 May; 141(5):659-71. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18410446) The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's 2008 Jun; oral vorinostat (suberoylanilide hydroxamic SAHA) in look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2008 Mar 05; 100(5):373. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18314478) Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Cancer 2008 Feb 01; 14(3):865-74. of lenalidomide in combination with dexamethasone for the treatment of multiple 2008 and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008 Apr; 22(4):842-9. View Prevention Dec; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18070708) From the bench to the bedside: emerging new treatments in multiple myeloma. Best Haematol. 2007 Dec; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17996594) The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant. 2008 Feb; 41(3):229-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17994121) The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008 Feb 01; 27(3):274-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17996017) Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008 Feb; 22(2):231-9. therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res. 2007 Oct 15; 13(20):6162-7. View MEK1/2 induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008 Aug 15; 112(4):1329-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17906076) Inhibition of Akt induces of survivin and cytotoxicity in human multiple myeloma J Haematol. 2007 138(6):783-91. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17760810) Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol. 2007 Sep; 82(9):831-3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17546639) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 15; 110(10):3557-60. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17690257) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007 Aug; 7(8):585-98. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17646864) Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007 Jul 01; 101(4):950-68. View 3-kinase Res. 2007 01; 13(13):3771-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17606706) Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal Nov; 21(11):2358-9. View in: absence 2007 Jun 01; 316(5829):1307-12. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17540897) Novel therapeutic avenues in myeloma: the treatment paradigm. Oncology (Williston hematopoietic stem cell transplantation: update on the use Hemost. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17602058) Does maintenance Sep 110(5):1656-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17510321) Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17402995) Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2007 Apr; 7(4):551-66. myeloma cells with beta-catenin/TCF pathway. Leukemia. 2007 Mar; 21(3):535-40. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17268521) The emerging role of novel therapies for the treatment of relapsed myeloma. J with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007 Feb; 13(2):183-96. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17241924) Phase III randomized trial of with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. Neuropharmacology. hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007 Jan; 92(1):95-100. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17229640) The treatment View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18024646) Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007 enhances 90 dexamethasone via of p38 mitogen-activated protein kinase/Hsp27 in multiple myeloma cell lines and inhibits paracrine tumour growth. safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007 Mar 15; 109(6):2604-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17138816) Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007 Jan; 21(1):151-7. View in: Smac/DIABLO as for multiple (MM). Blood. 2007 Feb 01; 109(3):1220-7. View in: bacteria. Proc Acad Sci S A. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17030793) A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor 26(16):2374-80. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17016430) Targets. inhibitor, blocks myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 01; 12(19):5887-94. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17020997) Recent advances in 6(8):1165-73. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16925483) International Leukemia. 2006 Sep; 20(9):1467-73. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16855634) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15; 108(10):3458-64. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16840727) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006 Jul 01; 66(13):6675-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16818641) Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response Haematologica. 2006 Jul; 91(7):929-34. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16818280) Oncol. 2006 Jun 20; View trial + bortezomib in relapsed refractory View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27955200) Impact of prior autologous stem cell transplant (ASCT) in patients receiving bortezomib or dexamethasone for relapsed/refractory multiple myeloma in Jun 24(18_suppl):7546. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27955445) Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and previously myeloma (MM): of a phase II multicenter study. Oncol. 2006 Jun 20; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27955336) Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant cancer Jun 20; 24(18_suppl):524. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27953576) The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006 Jul; 42(11):1564-73. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16765041) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Oncol. 2006 Jul 01; 24(19):3113-20. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16754936) Optimizing the efficacy and [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16832859) Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation. assimilation and analyses in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16533068) a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer. 2006 Mar 15; 106(6):1316-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16470606) FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol. 2006 Mar; 132(6):698-704. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16487170) Investig Drugs. 2006 Feb; 15(2):171-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16433596) Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol. 2006 Feb; an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. mediates antiangiogenesis via direct and indirect effects on endothelial cells. Cancer Res. 2006 Jan 01; 66(1):184-91. in severe hepatic veno-occlusive outcomes and mechanisms of action. Oligonucleotides. 2006; 16(1):105-14. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16584299) Resources dexamethasone: a new standard of care for initial therapy in multiple myeloma. J Clin Oncol. Res. 2005 Dec 15; 65(24):11712-20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16357183) New [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16506632) Safety of therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005 Nov 15; 104(10):2141-8. View A orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005 Nov; 8(5):407-19. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16286248) Antimyeloma bortezomib associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005 Oct; 131(1):71-3. resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005 Sep 15; 65(18):8350-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16166312) Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol. 2005 Sep 10; 23(26):6345-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16155018) Emerging trends in the in multiple myeloma cells and overcomes drug resistance. Cancer Res. 2005 Aug 15; 65(16):7478-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16103102) Risk factors and kinetics associated with bortezomib for relapsed, refractory Blood. 2005 Dec 01; 106(12):3777-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16099887) Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005 Nov 01; 106(9):2977-81. View Osteonecrosis of the jaw Engl Jul 07; 353(1):99-102; discussion View antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005 65(13):5898-906. View Med. 2005 Jun 16; 352(24):2487-98. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15958804) Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 15; multiple myeloma. Proc Acad View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15937109) Health-related quality with high-dose dexamethasone in relapsed myeloma 23(16_suppl):6535. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27943872) Preclinical evaluation of a novel and orally active proteasome inhibitor as a therapy in relapsed/refractory 2005 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27946115) Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma. J Clin Oncol. 2005 Jun; 23(16_suppl):6533. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27943870) Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27945581) Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. J Clin Oncol. 2005 Jun; 23(16_suppl):6501. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27943845) Bortezomib-associated J Clin Oncol. 2005 Jun; 23(16_suppl):6610. 17-AAG bortezomib (BZ) in patients with relapsed Ther. 2005 How to be moderately halophilic with broad salt tolerance: clues from the resistance multiple myeloma by induction of caspase-dependent and 01; 106(5):1794-800. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15870175) Case 1. Disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy. 2005 May PS-341 for overcoming resistance using lysophosphatidic acid in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer. 2005 Mar 15; 103(6):1195-200. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15690325) Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005 Jun 01; 105(11):4470-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15705788) Proteasome inhibition in the Feb; 4(2):290-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15655370) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005 Jan 20; 23(3):630-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15659509) Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005 Jan; 35(1):77-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15502851) Novel biological therapies for the multiple Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005 Jan; 128(2):192-203. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15638853) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-2004. A 40-year-old man with a large tumor of the skull. N Engl J Med. 2004 Dec 16; 351(25):2637-45. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15602025) against Nov 18; 23(54):8766-76. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15480425) inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res. 2004 Nov 15; 10(22):7540-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15569984) Efficacy, safety and tolerability of in patients rheumatoid arthritis. growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004 Oct 15; 64(20):7500-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15492276) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004 Oct; 127(2):165-72. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15461622) The DNA sequence and comparative analysis of human chromosome 5. Nature. 2004 Sep 16; 431(7006):268-74. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15372022) A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2004 View CC-5013 activity 2004 Dec 15; 104(13):4188-93. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15319277) Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function. Blood. 2005 Mar 01; 105(5):2235-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15292069) Bortezomib vs. dexamethasone in A randomized study. Aug 15; 22(16):3212-4. patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. Nov 01; 104(9):2886-92. View to bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. 2004 Oct 15; 104(8):2458-66. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15217830) An update of novel therapeutic approaches for multiple myeloma. Curr Treat Br J Haematol. 2004 May; 125(3):343-52. antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15087402) The DNA sequence and biology of human chromosome 19. Nature. 2004 Apr 01; 428(6982):529-35. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15057824) Pseudosubstrate peptides inhibit Akt Biochemistry. 2004 Feb 10; 43(5):1254-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14756561) Closing the gaps on human chromosome 19 revealed genes with a high density of repetitive tandemly arrayed elements. 15; 103(8):3158-66. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15070698) Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003 Dec 01; 63(23):8428-36. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14679006) Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant. 22(54):8797-801. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14647474) GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood. telomerase RNA in human multiple Res. 2003 Oct 01; 63(19):6187-94. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14559802) Immunomodulatory drug costimulates T Mar 103(5):1787-90. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14512311) Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. for the treatment of multiple myeloma and other cancers. Cancer Control. 2003 Sep-Oct; 10(5):361-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14581890) Novel strategies in the treatment of relapsed/refractory multiple myeloma. From the Multiple Myeloma Research Park). 2003 Aug; 17(8):1063-5. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12966673) Rev. 2003 Aug; 194:164-76. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12846814) study of bortezomib in relapsed, refractory myeloma. N Engl 26; is a potent deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12816865) Mechanisms of thermal adaptation revealed from the genomes the Antarctic Archaea Jun; 121(6):842-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12786794) gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 01; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12738663) Clinical update: deacetylase human 2003 15; 101(10):4055-62. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12531799) Hemostatic translocation of reverse transcriptase protein. Cancer Res. 2003 Jan 01; 63(1):18-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12517770) Identification of genes regulated (2ME2) in multiple myeloma cells using 01; genomic cells to chemotherapeutic agents: therapeutic applications. Blood. 15; 101(6):2377-80. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12424198) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002 Nov 01; 100(9):3063-7. View in: cells. Proc Acad S A. 2002 Oct 29; 99(22):14374-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12391322) Impact of supervision and self-assessment on doctor-patient communication in rural Mexico. Int J Qual Health Care. 2002 Oct; 14(5):359-67. View 2-Methoxyestradiol overcomes drug resistance in cells. Sep 15; 100(6):2187-94. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12200384) Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003 Jan 15; 101(2):703-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12393542) vivo and prolongs survival in a murine model. Cancer Res. Sep 01; 62(17):4996-5000. View PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26. View of intracellular anti-apoptotic via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12173037) Novel biologically based therapies inhibits growth of multiple myeloma cells in the bone marrow microenvironment. use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002 Dec 15; 100(13):4337-43. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12393437) Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002 Jul 01; 62(13):3876-82. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12097303) Apoptotic in myeloma cells: Biologic sequelae of nuclear factor-kappaB multiple Blood. 2002 Jun 01; 99(11):4079-86. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12010810) High-Throughput in: as a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10; 277(19):16639-47. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11872748) Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11840156) The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Blood Marrow Transplant. 2002; 8(4):198-205. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12017145) Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. Biol Blood Marrow Transplant. 2002; 8(6):326-33. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12108918) Randomized controlled trial to investigate influence of the fluid challenge on duration of hospital stay and perioperative morbidity in patients with hip fractures. Br J Anaesth. 2002 Jan; 88(1):65-71. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11881887) Thalidomide: Rev 2002; 53:629-57. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11818493) Adherence of marrow stromal cells upregulates vascular endothelial growth factor 2001 15(12):1950-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11753617) Novel therapies targeting the myeloma its microenvironment. Semin Oncol. 2001 Dec; 28(6):607-12. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11740818) Client communication behaviors with health care providers in Indonesia. Patient Educ Couns. 2001 Oct; 45(1):59-68. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11602369) A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies. Bone Marrow Transplant. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11593317) Species 07; 40(31):9125-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11478879) Acute liver failure as the initial manifestation of acute leukaemia. Liver. 2001 Aug; 21(4):287-92. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11454193) TRAIL/Apo2L ligand induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001 Aug 01; 98(3):795-804. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11468181) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001 Jul 27; 20(33):4519-27. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11494147) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001 Jul 15; 98(2):428-35. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11435313) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001 Jul 01; 98(1):210-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11418482) Clinical of trastuzumab and women with HER2-overexpressing metastatic breast PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001 Apr 01; 61(7):3071-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11306489) Initial sequencing and analysis of genome. Nature. 2001 Feb 15; 409(6822):860-921. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11237011) A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Bone Marrow Transplant. 2001 Feb; 27(3):269-78. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11277174) Thalidomide overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000 Nov 01; 96(9):2943-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11049970) A randomized trial of salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000 Sep; 109(4):267-76. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10996576) Discovery of a novel, paternally expressed ubiquitin-specific processing protease gene through comparative analysis of an imprinted region of mouse chromosome 7 and human chromosome 19q13.4. Genome Res. 2000 Aug; 10(8):1138-47. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10958632) Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplant. 2000 Jul; 26(2):169-76. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10918427) Dose-dependent effects of ketoprofen on gastric comparison with Nerve. 2000 Mar; 23(3):426-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10679720) Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin Cancer Res. 2000 Feb; 6(2):434-42. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10690521) Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. Cancer Chemother Pharmacol. 2000; 45(3):239-46. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10663642) cancer: a Biol Blood Marrow Transplant. 2000; 6(5):476-95. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11063377) The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol. 1999 Dec; 107(3):485-93. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10583247) The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses. Bone Marrow Transplant. 1999 Nov; 24(9):939-45. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10556951) (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Clin Cancer Res. 1999 Oct; 5(10):2735-41. View in: Single and PC7 in transected sciatic nerves and in nerve segments cultured in conditioned media: their presence in Schwann cells, macrophages, and smooth muscle cells. J Comp Neurol. 1999 Jan 25; 403(4):471-85. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9888313) relationship high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Sep; 4(9):2027-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9748116) Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature. Cancer. 1998 Aug 01; 83(3):409-14. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9690531) Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998 Aug 01; 92(3):737-44. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9680339) Cardiac protein use biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma 1998 Mar; 16(3):1000-7. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9508183) Drugs. Sep; 6(9):1143-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15991888) the tuberous sclerosis TSC1 on 9q34. Science. 1997 Aug 08; 277(5327):805-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9242607) High levels of incorrect use of car seat belts and child restraints in Fife--an important and under-recognised road safety issue. for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed extra cellular matrix proteins and platelet derived mitogens on human retinal pigment epithelial cell proliferation and contraction. Curr Eye Res. 1996 Jul; 15(7):739-48. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8670782) Ciliary neurotrophic factor, unlike nerve growth factor, supports neurite outgrowth but not synapse formation by adult Lymnaea neurons. J Neurobiol. 1996 Mar; 29(3):293-303. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8907159) Body experience differences of women preterm labor. of the presence of Coxsackie-B3 virus in endomyocardial biopsies from patients with myocarditis or trauma to the carotid artery: seven cases and a literature review. J Trauma. 1994 Feb; 36(2):265-72. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8114152) An observational study of car occupant restraint in Fife: impact of recent legislation. Public Health. 1993 Nov; 107(6):429-35. patients with prolymphocytic leukaemia: evidence for a selective expression of immunoglobulin variable region (IGV) gene products. Leuk Res. 1993 Aug; 17(8):669-76. View cross-reactive linked to the VHI subgroup in patients [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7686301) Rates of protein synthesis in different regions of the normotensive and hypertrophied heart in response to acute alcohol toxicity. Alcohol Alcohol. 1993 May; 28(3):297-310. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8352841) U S A. 1990 Nov; 87(22):8931-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2247468) A new biochemical engineering approach to the fractional precipitation of proteins. Biotechnol Bioeng. 1990 Aug 05; 36(4):354-66. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2111443) Stimulation of B-chronic lymphocytic leukemia populations by recombinant interleukin-4 and other defined growth-promoting agents. Leukemia. 1988 Mar; 2(3):165-70. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/3126369) Mycobacterium antigen antigenic study of human plasma cells in normal tissue and in myeloma: identification of a novel plasma cell associated antigen. Clin Exp Immunol. 1986 Jul; 65(1):112-9. View B cell leukaemia and lymphopenia in B cell neoplasia in adults: a study using the Kiel classification of non-Hodgkin's lymphoma. Br J Cancer. 1983 Aug; 48(2):185-93. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/6603860) Women's perceptions of change in relationships shared with children during pregnancy. Matern Child Nurs J. 1983; 12(2):75-88. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/6554427) "}